Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Shock ; 20(2): 154-8, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12865660

ABSTRACT

Endogenous copper can play an important role in postischemic reperfusion injury, a condition associated with endothelial cell activation and increased interleukin 8 (IL-8) production. Excessive endothelial IL-8 secreted during trauma, major surgery, and sepsis may contribute to the development of systemic inflammatory response syndrome (SIRS), adult respiratory distress syndrome (ARDS), and multiple organ failure (MOF). No previous reports have indicated that copper has a direct role in stimulating human endothelial IL-8 secretion. Increased IL-8 in the culture medium of human umbilical vein (HUVEC), lung microvascular, and iliac artery endothelial cells was observed 24 h after the addition of 10 to 50 microM CuCl2 (cupric ions). HUVEC IL-8 induction by copper was higher than by 50 pg/mL tumor necrosis factor-alpha, whereas 50 pg/mL IL-1beta and 1 ng/mL platelet-activating factor did not stimulate IL-8 production or release. HUVEC IL-8 mRNA increased 3 h after CuCl2 stimulation and remained elevated after 24 h, implying sustained transcriptional activation. Copper did not stimulate HUVECs to secrete other cytokines. Cu(II) appeared to be the primary copper ion responsible for the observed increase in IL-8 because a specific high-affinity Cu(II)-binding peptide, d-Asp-d-Ala-d-His-d-Lys (d-DAHK), completely abolished this effect in a dose-dependent manner. These results suggest that Cu(II) may induce endothelial IL-8 by a mechanism independent of known Cu(I) generation of reactive oxygen species. Furthermore, in vivo studies are warranted to determine if copper is involved in the pathogenesis of systemic inflammation and if Cu(II) chelation can reduce this IL-8-induced endothelial inflammatory response.


Subject(s)
Copper/pharmacology , Endothelium, Vascular/metabolism , Inflammation , Interleukin-8/metabolism , Umbilical Veins/cytology , Cells, Cultured , Copper/chemistry , Copper/metabolism , Culture Media/pharmacology , Cytokines/biosynthesis , Dose-Response Relationship, Drug , Eicosanoids/metabolism , Enzyme-Linked Immunosorbent Assay , Humans , Interleukin-1/metabolism , Oligopeptides/chemistry , Peptides/chemistry , Platelet Activating Factor/metabolism , RNA, Messenger/metabolism , Reactive Oxygen Species , Reverse Transcriptase Polymerase Chain Reaction , Time Factors , Transcriptional Activation , Tumor Necrosis Factor-alpha/metabolism
2.
Biochem Biophys Res Commun ; 290(5): 1388-92, 2002 Feb 08.
Article in English | MEDLINE | ID: mdl-11820775

ABSTRACT

Activated protein C (APC) is useful in the treatment of sepsis. Ischemia and acidosis, which often accompany sepsis, cause the release of copper from loosely bound sites. We investigated (i) whether physiological concentrations of copper inhibit APC anticoagulant activity and (ii) if any copper-induced APC inhibition is reversible by human serum albumin (HSA) or a high-affinity copper-binding analogue of the human albumin N-terminus, d-Asp-d-Ala-d-His-d-Lys (d-DAHK). APC activity after 30 min of incubation with CuCl2 (10 microM) was decreased 26% below baseline. HSA, both alone and when combined with various ratios of CuCl2, increased APC activity significantly above baseline. d-DAHK alone and 2:1 and 4:1 ratios of d-DAHK:CuCl2 also increased APC activity. APC contained 1.4 microM copper, which helps explain the increased APC activity with HSA and d-DAHK alone. These in vitro results indicate that copper inhibits APC activity and that albumin and d-DAHK reverse the copper-induced APC deactivation.


Subject(s)
Copper/metabolism , Copper/pharmacology , Enzyme Inhibitors/pharmacology , Oligopeptides/metabolism , Oligopeptides/pharmacology , Protein C/antagonists & inhibitors , Protein C/metabolism , Serum Albumin/pharmacology , Binding Sites , Copper/antagonists & inhibitors , Enzyme Activation/drug effects , Enzyme Inhibitors/metabolism , Humans , Protein Binding , Serum Albumin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...